Cis-3, 4′, 5-Trimethoxy-3′-aminostilbene disrupts tumor vascular perfusion without damaging normal organ perfusion

Cancer Chemotherapy and Pharmacology

Volumn 63, Issue 2, 2009, Pages 191-200

  Durrant, David ^a   Corwin, Frank ^b   Simoni, Daniele ^c   Zhao, Ming ^d   Rudek, Michelle A ^d   Salloum, Fadi N ^a   Kukreja, Rakesh C ^a   Fatouros, Panos P ^b   Lee, Ray M ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c UNIVERSITY OF FERRARA   (Italy)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Bevacizumab; DCE MRI; Endothelial cells; Stilbenes; Tumor perfusion

Indexed keywords

3,4',5 TRIMETHOXY 3' AMINOSTILBENE; 3,4',5 TRIMETHOXY 3' HYDROXYSTILBENE; BEVACIZUMAB; CD34 ANTIGEN; COLCHICINE; N ACETYLCOLCHINOL PHOSPHATE; STILBENE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DOPPLER ECHOCARDIOGRAPHY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG STRUCTURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN PERFUSION; OVARY CANCER; PRIORITY JOURNAL; TUMOR BLOOD FLOW; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD34; APOPTOSIS; CELL LINE, TUMOR; ENDOTHELIAL CELLS; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR STRUCTURE; NEOPLASM TRANSPLANTATION; NEOPLASMS; ORGAN SPECIFICITY; REGIONAL BLOOD FLOW; STILBENES; TISSUE DISTRIBUTION; ULTRASONOGRAPHY, DOPPLER; UMBILICAL VEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 57149142361     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0726-6     Document Type: Article

References (26)

1. A Eberhard 2000 Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies Cancer Res 60 5 1388 1393
2. DM McDonald PL Choyke 2003 Imaging of angiogenesis: from microscope to clinic Nat Med 9 6 713 725
3. P Carmeliet RK Jain 2000 Angiogenesis in cancer and other diseases Nature 407 6801 249 257
4. A Bikfalvi R Bicknell 2002 Recent advances in angiogenesis, anti-angiogenesis and vascular targeting Trends Pharmacol Sci 23 12 576 582
5. D Neri R Bicknell 2005 Tumour vascular targeting Nat Rev Cancer 5 6 436 446
6. GM Tozer C Kanthou BC Baguley 2005 Disrupting tumour blood vessels Nat Rev Cancer 5 6 423 435
7. JP Stevenson 2003 Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow J Clin Oncol 21 23 4428 4438
8. MM Cooney 2004 Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer Clin Cancer Res 10 1 Pt 1 96 100
9. GJ Rustin 2003 Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results J Clin Oncol 21 15 2815 2822
10. LV Beerepoot 2006 Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors J Clin Oncol 24 10 1491 1498
11. HL Anderson 2003 Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate J Clin Oncol 21 15 2823 2830
12. Y Shaked 2006 Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors Science 313 5794 1785 1787
13. M Roberti 2003 Synthesis and biological evaluation of resveratrol and analogues as apoptosis-inducing agents J Med Chem 46 16 3546 3554
14. AJ Bailer 1988 Testing for the equality of area under the curves when using destructive measurement techniques J Pharmacokinet Biopharm 16 3 303 309
15. N Weidner 1991 Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma N Engl J Med 324 1 1 8
16. N Weidner 1992 Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma J Natl Cancer Inst 84 24 1875 1887
17. NB Schiller 1989 Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms J Am Soc Echocardiogr 2 5 358 367
18. LE Teichholz 1976 Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy Am J Cardiol 37 1 7 11
19. RB Devereux 1986 Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings Am J Cardiol 57 6 450 458
20. GR Pettit 1989 Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4 Experientia 45 2 209 211
21. RT Dorr 1996 Antitumor activity of combretastatin-A4 phosphate, a natural product tubulin inhibitor Invest New Drugs 14 2 131 137
22. GG Dark 1997 Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature Cancer Res 57 10 1829 1834
23. JA Garcia BI Rini 2007 Recent progress in the management of advanced renal cell carcinoma CA Cancer J Clin 57 2 112 125
24. BI Rini 2007 Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions Clin Cancer Res 13 4 1098 1106
25. T Force DS Krause RA Van Etten 2007 Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition Nat Rev Cancer 7 5 332 344
26. CG Willett 2004 Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat Med 10 2 145 147